Blog
RSS FeedPosted by Michael Wonder on 06 Jul 2020
The development of COVID-19 vaccines: safeguards needed
6 July 2020 - A safe and effective vaccine against coronavirus disease 2019 (COVID-19) is the best way to control and ...
Posted by Michael Wonder on 06 Jul 2020
Developing a SARS-CoV-2 vaccine at warp speed
6 July 2020 - The coronavirus disease 2019 (COVID-19) pandemic has unleashed major and substantial changes in the provision of health ...
Posted by Michael Wonder on 06 Jul 2020
Pharma industry seizes on pandemic as a shot at redemption
6 July 2020 - It is almost five years since Hillary Clinton sent her $15 billion tweet. ...
Posted by Michael Wonder on 06 Jul 2020
EspeRare receives FDA breakthrough therapy designation for investigational prenatal treatment ER-004 in X-linked hypohidrotic ectodermal dysplasia
6 July 2020 - EspeRare today announced that the U.S. FDA has granted breakthrough therapy designation to investigational ER-004 protein ...
Posted by Michael Wonder on 06 Jul 2020
Will we be hostages to drug makers’ Covid vaccine pricing?
6 July 2020 - The United States is the only developed nation unable to balance cost, efficacy and social good in ...
Posted by Michael Wonder on 05 Jul 2020
FDA Commissioner says he can't predict when vaccine will be ready after Trump's timeline claims
5 July 2020 - Food and Drug Administration Commissioner Stephen Hahn said Sunday that he would not make a prediction ...
Posted by Michael Wonder on 03 Jul 2020
FDA approves new HIV treatment for patients with limited treatment options
2 Jul 2020 - Today, the U.S. FDA approved Rukobia (fostemsavir), a new type of anti-retroviral medication for adults living with ...
Posted by Michael Wonder on 03 Jul 2020
MetVital announces FDA fast track designation of anhydrous enol-oxaloacetate for the treatment of patients with newly diagnosed glioblastoma multiforme
1 July 2020 - MetVital today announces that the U.S. FDA has notified MetVital that its lead drug candidate, "Anhydrous ...
Posted by Michael Wonder on 02 Jul 2020
Regression discontinuity design
2 July 2020 - The method is used to study the outcomes related to an abrupt change when it is not ...
Posted by Michael Wonder on 02 Jul 2020
Acacia Pharma announces US FDA approval of Byfavo (remimazolam) for injection for the induction and maintenance of procedural sedation
2 July 2020 - Byfavo is a very rapid onset/offset IV benzodiazepine sedative for use during invasive medical procedures lasting 30 ...
Posted by Michael Wonder on 02 Jul 2020
Rhythm Pharmaceuticals receives rare paediatric disease designation from U.S. FDA for setmelanotide for treatment of POMC and LEPR deficiency obesities
1 July 2020 - Rhythm Pharmaceuticals today announced that the U.S. FDA has granted rare paediatric disease designations for setmelanotide, an ...
Posted by Michael Wonder on 02 Jul 2020
scPharmaceuticals announces Furoscix NDA resubmission
1 July 2020 - scPharmaceuticals today announced that it has resubmitted its 505(b)(2) new drug application to the U.S. FDA seeking ...
Posted by Michael Wonder on 01 Jul 2020
Blueprint Medicines announces submission of new drug application to FDA for pralsetinib for the treatment of advanced RET mutant and RET fusion positive thyroid cancers
1 July 2020 - Blueprint Medicines today announced the submission of a new drug application to the U.S. FDA for ...
Posted by Michael Wonder on 01 Jul 2020
FDA approves Bavencio as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma
30 June 2020 - First and only FDA approved immunotherapy to demonstrate a significant overall survival benefit in the first-line setting ...
Posted by Michael Wonder on 01 Jul 2020
Y-mAbs announces initiation of submission of omburtamab rolling biologics license application to the FDA
30 June 2020 - Y-mAbs Therapeutics today announced that the Company has initiated the submission of its biologics license application ...